

In re Application of: Tami HAREL et al
Serial No.: 10/804,560
Filed: March 18, 2004
Office Action Mailing Date: August 8, 2007

Examiner: Michael William Kahelin
Group Art Unit: 3762
Attorney Docket: 34487

In the Claims:

1 - 51. (Cancelled)

52. (Currently Amended) Apparatus for blood glucose control, comprising:

at least one implantable electrode adapted to apply an electric field to a pancreas; and

circuitry adapted to electrify said at least one electrode and configured to electrify said electrode in a manner which generates an electric field that significantly reduces elevated blood glucose levels, said circuitry configured to apply said field also when glucose levels are not elevated.

53. (Original) Apparatus according to claim 52, wherein said circuitry is a closed loop system including sensing of the effect of the electrification and wherein said circuitry is configured to over stimulate in cases of doubt.

54. (Original) Apparatus according to claim 52, wherein said circuitry is a semi-open loop system where a relatively long stimulation series is applied without feedback.

55. (Original) Apparatus according to claim 52, wherein said circuitry is an open loop system where a stimulation series is applied responsive to a trigger and without feedback.

In re Application of: Tami HAREL et al
Serial No.: 10/804,560
Filed: March 18, 2004
Office Action Mailing Date: August 8, 2007

Examiner: Michael William Kahelin
Group Art Unit: 3762
Attorney Docket: 34487

56 - 78. (Cancelled)

79. (Currently Amended) Apparatus according to claim 52, wherein said circuitry ~~compensates by reducing~~ is configured to electrify said electrode in a manner which generates an electric field that reduces glucose levels in a non-insulin manner.

80. (Currently Amended) Apparatus according to claim 52, wherein said circuitry ~~compensates~~ is configured to electrify said electrode in a manner which generates an electric field that reduces ~~by reducing~~ glucagon secretion.

81. (Currently Amended) Apparatus according to claim 52, wherein said circuitry configured to electrify said electrode in a manner which generates an electric field that reduces or prevents a substantial increase in insulin secretion, ~~during said compensation.~~

82. (Previously Presented) Apparatus according to claim 52, wherein said apparatus is programmed with a knowledge of a slow acting chemical-based insulin therapy provided to said pancreas.

83. (Previously Presented) Apparatus according to claim 52, comprising an automatic glucose sensor for automatically detecting a situation requiring an acute response.

In re Application of: Tami HAREL et al
Serial No.: 10/804,560
Filed: March 18, 2004
Office Action Mailing Date: August 8, 2007

Examiner: Michael William Kahelin
Group Art Unit: 3762
Attorney Docket: 34487

84. (Previously Presented) Apparatus according to claim 52, comprising an automatic glucose sensor for automatically detecting a situation requiring an acute insulin response.

85. (Currently Amended) Apparatus according to claim 52, wherein said field acts as response is an acute insulin response in reducing glucose levels.

86. (Previously Presented) Apparatus according to claim 52, wherein said electrode is adapted for attachment to a pancreas.

87. (Previously Presented) Apparatus according to claim 52, wherein said electrode is adapted for attachment to a muscular organ.

88 - 100. (Cancelled)

101. (New) An apparatus according to claim 52, wherein said field reduces elevated blood glucose levels by at least 20% of an elevation of the glucose level above a fasting baseline glucose level.

102. (New) Apparatus according to claim 52, wherein said circuitry configured to electrify said electrode in a manner which generates an electric field that reduces blood insulin levels, as measured by an accumulated amount for a glucose ingestion event and in comparison to a regular response of said person, by more than 20%.